Reaction

Brugada Syndrome reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,010 reports · 21 co-occurring drugs

As of the last recalculation, Brugada Syndrome appears in 1,010 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is LITHIUM CARBONATE (PRR 47.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Lithium Carbonate3847.948.0
Guanfacine1231.831.8
Lamotirigine9530.130.1
Lamotrigine Extended-Release9530.130.1
Lamotrigine Chewable Dispersible9530.130.1
Propofol4929.029.0
Lithium3126.126.1
Lithium Bromatum3126.126.1
Sevoflurane1025.025.1
Doxepin1224.724.7
Testosterone2522.622.6
Loperamide Hydrochloride Oral1122.422.5
Doxepin Hydrochloride1321.521.5
Valproate Sodium2121.421.4
Bupropion4421.221.3
Sumatriptan Succinate2319.219.2
Loperamide Hcl1117.817.8
Lamotrigine9816.916.9
Ranolazine815.915.9
Norepinephrine611.611.6
Norepinephrine Bitartrate811.511.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.